Continuous Glucose Monitoring for Diabetes

Recruiting at 16 trial locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: Bionime Corporation

No Placebo Group

Trial Summary

What is the purpose of this trial?

The purpose of this study is to evaluate the effectiveness and safety of the RIGHTEST Continuous Monitoring (CGM) System in adult population with diabetes mellitus.

Eligibility Criteria

Adults with either Type 1 or Type 2 diabetes who can attend all study visits, wear two sensors on their arms, and understand English. They must be willing to provide written consent and able to follow device instructions.

Inclusion Criteria

Subjects must be willing and able to provide signed written consent

Subjects must be available to participate in all clinical sessions

Subjects must be able to speak, read, and write English

Exclusion Criteria

I have been diagnosed with hemophilia or another bleeding disorder.

Any condition that, in the opinion of the Investigator, would interfere with participation in the study or pose excessive risk to study staff

Plans to donate blood during the study

Treatment Details

Interventions

• RIGHTEST Continuous Glucose Monitoring System (Continuous Glucose Monitoring System)

Trial Overview The trial is testing the RIGHTEST Continuous Glucose Monitoring System's effectiveness and safety in managing blood glucose levels for adults with diabetes.

Participant Groups

Group I: CGM System Experimental Treatment 1 Intervention

Blood draw and glucose challenge will be performed to evaluate the performance of the CGM system compared to reference measurements during the in in-clinic visits.

Who Is Running the Clinical Trial?

Bionime Corporation

Lead Sponsor

Trials

4

Recruited

370+